Joyzyme Group Stock

Joyzyme Group ROE

The Return on Equity (ROE) of Joyzyme Group (8622.HK) as of Aug 2, 2026 is -9.79 %. In the previous year, Return on Equity (ROE) was -7.69 % — a change of 27.21% (lower).

ROE

-9.79 %

YoY

27.21%

Last updated:

In 2026, Joyzyme Group's return on equity (ROE) was -9.79 %, a 27.21% increase from the -7.69 % ROE in the previous year.

Access this data via the Eulerpool API

Joyzyme Group Stock analysis

What does Joyzyme Group do? Huakang Biomedical Holdings Co Ltd is a leading company in the field of biomedical research and development. It was founded in 2004 and is headquartered in Shenzhen, China. The company is listed on the Hong Kong Stock Exchange (HKEX: 8622) and has branches in various countries, including Germany and the USA. Answer: Huakang Biomedical Holdings Co Ltd is a leading company in the field of biomedical research and development. It was founded in 2004 and is headquartered in Shenzhen, China. The company is listed on the Hong Kong Stock Exchange (HKEX: 8622) and has branches in various countries, including Germany and the USA. Joyzyme Group is one of the most popular companies on Eulerpool.

ROE Details

Decoding Joyzyme Group's Return on Equity (ROE)

Joyzyme Group's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Joyzyme Group's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Joyzyme Group's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Joyzyme Group’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Joyzyme Group stock

Return on Equity (ROE) of Joyzyme Group is -9.79 % in 2026.

Access this data via the Eulerpool API

Profitability — Joyzyme Group

All Key Metrics — Joyzyme Group